Hyperprolactinemia and possibly related development of prolactinoma during                 amisulpride treatment; three cases

Akkaya, Cengiz; KAYA, Büşra; Kotan, Zeynep; Sarandöl, Aslı; Ersoy, Canan; Kırlı, Selçuk

doi:10.1177/0269881108091252

Cited by 17 publications

(38 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the contrary, partial D2 agonists, such as ARI, BRE, and CAR, can lower prolactin levels, even below drug-free baseline, and adjunctive ARI has been shown to decrease hyperprolactinemia associated with other antipsychotics 28,209–211. Several cases have been reported describing antipsychotic use and prolactinoma,212 in particular in cases using AMI213,214 or RIS 215–217. However, no solid data are available, and thus, no conclusions can be drawn on the association of antipsychotics and prolactinoma 218…”

Section: Methodsmentioning

confidence: 99%

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

Solmi

Murru

Pacchiarotti

et al. 2017

TCRM

325

244

View full text Add to dashboard Cite

Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs) have revolutionized psychiatric care in terms of facilitating discharge from hospital and enabling large numbers of patients with severe mental illness (SMI) to be treated in the community. Second-generation antipsychotics (SGAs) ushered in a progressive shift from the paternalistic management of SMI symptoms to a patient-centered approach, which emphasized targets important to patients – psychosocial functioning, quality of life, and recovery. These drugs are no longer limited to specific Diagnostic and Statistical Manual of Mental Disorders (DSM) categories. Evidence indicates that SGAs show an improved safety and tolerability profile compared with FGAs. The incidence of treatment-emergent extrapyramidal side effects is lower, and there is less impairment of cognitive function and treatment-related negative symptoms. However, treatment with SGAs has been associated with a wide range of untoward effects, among which treatment-emergent weight gain and metabolic abnormalities are of notable concern. The present clinical review aims to summarize the safety and tolerability profile of selected FGAs and SGAs and to link treatment-related adverse effects to the pharmacodynamic profile of each drug. Evidence, predominantly derived from systematic reviews, meta-analyses, and clinical trials of the drugs amisulpride, aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, ziprasidone, CPZ, haloperidol, loxapine, and perphenazine, is summarized. In addition, the safety and tolerability profiles of antipsychotics are discussed in the context of the “behavioral toxicity” conceptual framework, which considers the longitudinal course and the clinical and therapeutic consequences of treatment-emergent side effects. In SMI, SGAs with safer metabolic profiles should ideally be prescribed first. However, alongside with safety, efficacy should also be considered on a patient-tailored basis.

show abstract

Section: Methodsmentioning

confidence: 99%

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

Solmi

Murru

Pacchiarotti

et al. 2017

TCRM

325

244

View full text Add to dashboard Cite

show abstract

“…A recent case series is suggestive that amisulpride may also be associated with the development of prolactinomas mediated via hyperprolactinaemia. 61 Neither clinical studies nor epidemiologic studies conducted to date have shown a definitive association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time. .........................................................................................................................................…”

Section: Longer Term Consequences Of Hyperprolactinaemia Bonementioning

confidence: 99%

A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry?

Bushe

Bradley

Pendlebury³

2010

Ann Clin Biochem

View full text Add to dashboard Cite

Hyperprolactinaemia is a common adverse event reported in association with treatments used in schizophrenia and bipolar disorder. Recent data are suggestive that hyperprolactinaemia may have a range of significant short-and long-term clinical consequences. The objective of this review is to examine the causes, frequency and clinical consequences of hyperprolactinaemia in the severely mentally ill (SMI) with a focus on patients taking antipsychotic medications. A Medline search was carried out to identify relevant publications. Reference lists from previous review articles were also examined to search for additional data. Hyperprolactinaemia may be one of the most common adverse events associated with some antipsychotic medications. Precise rates with individual drugs had however until recently been poorly categorized. The relationship between hyperprolactinaemia and adverse outcomes in the SMI population appears similar to that in the general population. Adverse outcomes (such as sexual dysfunction) can occur acutely and in the longer term (bone fractures and possibly breast cancer), but the precise link between degree and length of hyperprolactinaemia and adverse outcome remains to be established. In conclusion, hyperprolactinaemia is a common treatment-emergent adverse event of some antipsychotic medications and may have clinical consequences. Physicians must balance the benefits and risks of treatment when determining appropriate therapy for individual patients.

show abstract

“…The US Food and Drug Administration Adverse Event Reporting System pharmacovigilance database study strongly linked risperidone (adjusted reporting ratio 18.7) with the highest frequency of pituitary adenomas compared with haloperidol (5.6), ziprasidone (3.0) and olanzapine (2.3) (Szarfman et al, 2006). A recent case series is suggestive that amisulpride may also be associated with the development of prolactinomas mediated via hyperprolactinaemia (Akkaya et al, 2009). The multiple actions of prolactin and relative lack of research into hyperprolactinaemia suggest that additional potential long-term effects may be discovered potentially in glands such as the thyroid.…”

Section: Possible Association With Cancermentioning

confidence: 99%

Prolactin and Schizophrenia, an Evolving Relationship

Bushe¹,

Pendlebury²

2011

Health Management - Different Approaches and Solutions

View full text Add to dashboard Cite

Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases

Cited by 17 publications

References 21 publications

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry?

Prolactin and Schizophrenia, an Evolving Relationship

Contact Info

Product

Resources

About